Biomérieux, Evotec and Boehringer Ingelheim team up in new €40m joint venture
The companies Biomériux, Evotec and Boehringer Ingelheim have joined forces against AMR and announced the launch of a new company, Aurobac Therapeutics SAS, which will develop antimicrobial resistance diagnostics and AMR therapies.
Aurobac Therapeutics will unite the best knowledge of the three founding companies to develop a new precision medicine approach, from diagnosis to cure. The ultimate goal is to succeed in the fight against AMR which is a major public health threat, endangering the advancements of modern medicine.
“The grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial therapies. We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMérieux, to combine our complementary strengths. By leveraging Evotec’s multimodality approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR”, said Werner Lanthaler, CEO of Evotec.